Although based on a small sample of six patients, the favorable effectiveness profile of CBD in individuals with PAFAH1B1 pathogenic variants, typically associated with malformations of cortical development, suggests a potential role for CBD in epilepsies with combined structural and genetic etiologies, similar to its observed effects in TSC. Here, PAFAH1B1 is linked to tuberous sclerosis.